このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CARまたは養子細胞療法の製造のための白血球除去

2026年11月6日 更新者:National Cancer Institute (NCI)

Background:

Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy. CAR-T therapy may be offered to people when their cancer comes back. The collected T-cells are used to make a special version of T-cells called CARs. Researchers want to collect these cells from people who may become eligible for a CAR T-cell study in the future.

Objective:

To identify people who have a high likelihood to benefit from CAR T-cell therapy early in their disease course and collect and store a T-cell product.

Eligibility:

People ages 3-65 with a form of leukemia or lymphoma that has not been cured by standard therapy

Design:

Participants will be screened with medical history, physical exam, and blood and urine tests. Review of existing MRI, x-ray, pathology specimens/reports or CT images may be done.

On this study, participants will have leukapheresis. A needle will be placed into the arm. Blood will be collected and go through a machine. White blood cells will be taken out by the machine. The plasma and red cells will be returned to the participant through a second needle in the other arm. The procedure will take 4-6 hours. Some participants may have a central line (catheter) inserted which is needed to do the leukapheresis procedure, instead of the needles in the arms-especially if they are smaller. For a central line placement, a long thin tube is inserted through a small incision into the main blood vessel leading into the heart that would allow access to the blood to do the leukapheresis procedure.

Participants cells will be processed and frozen for future use in a CAR T-cell therapy study.

...

調査の概要

詳細な説明

Background:

  • Leukapheresis is a necessary step to developing a "CAR therapy" or other adoptive cellular therapy products. There are numerous clinical trials underway in the NCI utilizing CAR therapy.

  • The purpose of this protocol is to develop a streamlined process whereby patients undergo apheresis for development of a CAR cell or other adoptive cell therapy product on a subsequent therapeutic clinical trial, which can be administered when the patient needs investigational therapies.

  • Emerging data suggests the critical importance of elements of the apheresis product in outcomes following adoptive cell therapy. Evaluation of methodologies to optimize timing and composition of the apheresis collection are imperative to the feasibility of manufacturing and remains an active area of investigations. Patient specific elements (e.g., presence of NK-cells/circulating leukemic blasts and/or inhibitory myeloid derived suppressor cells) along with other parameters of the apheresis product itself appear to influence efficacy and toxicity profiles of adoptive cell therapy.

  • Allowing for collection of the leukapheresis product in a protocol separate from the therapeutic protocol would allow for the best optimization of:

    • Patient care and disease burden
    • Timing and coordination of cell infusion
    • Collection in patients with high-risk disease who have no current detectable disease but have a very high likelihood of relapse.
    • Comprehensive evaluation of apheresis products will facilitate enhanced understanding of critical elements of the apheresis product in patients with cancer and how this may impact outcomes of adoptive cell therapy.

Objective:

To obtain via the leukapheresis process by which cells will be collected and stored for use in CCR CAR or other adoptive cell therapy clinical trials.

Eligibility:

Patients >=3 - <=65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responding to at least one or more standard regimen.

Design:

-Once a patient is identified to be a future potential candidate for one of the NCI CAR or other adoptive cell therapy clinical trials, they will undergo leukapheresis, as estimated by recipient weight and target cell harvest dose in the Department of Transfusion Medicine

(DTM).

-No treatments, investigational or standard therapy will be administered on this protocol beyond those used to support the apheresis procedure.

研究の種類

観察的

入学 (推定)

120

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~65年 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients 3-65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy and who meet all eligibility criteria are eligible to participate.

説明

  • INCLUSION CRITERIA:

  • Age: >= 3 and <= 65 years

  • Weight >= 15 kg

  • Confirmation of cancer diagnosis provided by disease-specific assessment (e.g., flow cytometry, PCR) or H&E verification.

  • Disease Status:

    • Relapsed/refractory cancer that has failed at least one standard regimen and are not in remission at the time of leukapheresis, OR
    • Previously treated patients without detectable disease at the time of leukapheresis but at high-relapse risk.
  • Potentially eligible for future NIH-CAR or other adoptive cell therapy based on the following:

    • Adequate performance status: Patients > 10 years of age: Karnofsky >= 50%; Patients <= 10 years of age: Lansky scale >= 50%

    • Adequate organ function:

      • absolute neutrophil count >750/mcL*
      • platelets >=30,000/mcL*
      • total bilirubin <=2 X ULN (except in the case of subjects with documented Gilbert s disease > 3x ULN)

AST(SGOT)/ALT(SGPT)<=20 X institutional upper limit of normal for age and laboratory normal ranges

creatinine within age adjusted normal institutional limits (see below) OR

creatinine clearance >= 60 mL/min/1.73 m^2 for creatinine levels above institutional normal.

  • Age (Years): <=5; Maximum Serum Creatine (mg/dL): 0.8

  • Age (Years): 5 < age <= 10; Maximum Serum Creatine (mg/dL): 1.0

  • Age (Years): >10; Maximum Serum Creatine (mg/dL): 1.2

    • Cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion.

      • Patients, parents/guardians, legally authorized representative (LAR), or durable power of attorney must be able to give consent and sign the Informed Consent Document.

EXCLUSION CRITERIA:

  • Transfusion refractory thrombocytopenia such that platelet count cannot be adequately supported with transfusions to be at >=30,000/mcL
  • Active DIC, bleeding or coagulopathy which cannot be corrected with minimal intervention
  • Rapidly progressive disease or hyperleukocytosis >= 50,000 blasts/mcL
  • Symptomatic, uncontrolled or severe intercurrent illness that would compromise the ability to tolerate CAR or adoptive cell therapy-based toxicity
  • Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met. Cytopenias deemed to be disease-related and not therapyrelated are exempt from this exclusion.
  • Pregnant or nursing (lactating) individuals, where pregnancy is defined as the state of after conception and until the termination of gestation, confirmed by a positive hCG laboratory test at screening
  • Active or latent hepatitis B or active hepatitis C, or any uncontrolled infection at screening
  • Human Immunodeficiency Virus (HIV) infection at screening (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
  • Any patient that in the opinion of the investigator is not medically stable to undergo the leukapheresis procedure or will not comply with the visit schedules or procedures

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
1

Patients >/=3 - </=65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to at least one standard regimen

Leukapheresis

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
fraction of subjects who can enroll on a CAR-T study within approximately 12 months of undergoing apheresis
時間枠:12 months after collection of apheresis product

number of subjects who enroll on a CAR-T study within approximately 12 months of undergoing apheresis

12 months after collection of apheresis product

二次結果の測定

結果測定
メジャーの説明
時間枠
fraction of patients who experience a grade 4 toxicity associated with apheresis
時間枠:completion of apheresis procedure

number of patients who experience an unexpected grade 4 toxicity associated with apheresis

completion of apheresis procedure
fraction of patients who can enroll on a CAR/adoptive cell therapy study within 12 months of undergoing apheresis by disease and type of CAR to be received.
時間枠:12 months after collection of apheresis product

number of patients who can enroll on a CAR/adoptive cell therapy study within 12 months of undergoing apheresis by disease and type of CAR to be received

12 months after collection of apheresis product

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Srivandana Akshintala, M.D.、National Cancer Institute (NCI)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年8月14日

一次修了 (推定)

2030年1月31日

研究の完了 (推定)

2030年7月31日

試験登録日

最初に提出

2017年7月21日

QC基準を満たした最初の提出物

2017年7月21日

最初の投稿 (実際)

2017年7月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年10月27日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD 共有時間枠

Clinical data available during the study and indefinitely.

IPD 共有アクセス基準

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する